Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-MUC16, ACA125 Vector   (CAT#: GTVCR-WQ244MR)

This product GTVCR-WQ244MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting MUC16. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Mus musculus
RefSeq NM_024690.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 94025
UniProt ID Q8WXI7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-MUC16, ACA125 Vector (GTVCR-WQ244MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ930MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL17A&IL17F, CDP4940 Vector Vector CDP4940
GTVCR-WQ2224MR IVTScrip™ pT7-VEE-mRNA-Anti-PTK7, PF-06523435 Vector Vector PF-06523435
GTVCR-WQ2654MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD19, XmAb5871 Vector Vector XmAb5871
GTVCR-WQ1422MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD274, HTI-1088 Vector Vector HTI-1088
GTVCR-WQ983MR IVTScrip™ pT7-VEE-mRNA-Anti-CD40, CHIR-12,12 Vector Vector CHIR-12,12
GTVCR-WQ2225MR IVTScrip™ pSP6-VEE-mRNA-Anti-PTK7, PF-06523435 Vector Vector PF-06523435
GTVCR-WQ2324MR IVTScrip™ pT7-VEE-mRNA-Anti-PDGFRB, REGN-2176 Vector Vector REGN-2176
GTVCR-WQ165MR IVTScrip™ pSP6-VEE-mRNA-Anti-EGFR, ABBV-321 Vector Vector ABBV-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW